8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):  02/05/2013

LA JOLLA PHARMACEUTICAL COMPANY

(Exact name of registrant as specified in its charter)

Commission File Number:  0-24274

CALIFORNIA	33-0361285
(State or other jurisdiction of	(IRS Employer
incorporation)	Identification No.)

4370 La Jolla Village Drive, Suite 400, San Diego, California 92122

(Address of principal executive offices, including zip code)

(858) 207-4264

(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[  ]   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[  ]   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[  ]   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[  ]   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01.    Other Events

On February 5, 2013, La Jolla Pharmaceutical Company (the "Company") issued a press release. A copy of the press release is attached as Exhibit 99.1 to this Form 8-K.

Item 9.01.    Financial Statements and Exhibits

(d) Exhibits. The following exhibit is filed with this report on Form 8-K:

       Exhibit 99.1 Press Release dated February 5, 2013.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

		LA JOLLA PHARMACEUTICAL COMPANY
Date: February 05, 2013	By:	/s/    George Tidmarsh
		George Tidmarsh
		President and Chief Executive Officer

EXHIBIT INDEX

Exhibit No.	Description
EX-99.1	Press release dated February 5, 2013

EX-99

La Jolla Pharmaceutical Company Receives Notice of Allowance for Patent Covering Modified Pectin Compositions

SAN DIEGO, CA. - (MARKETWIRE-February 5, 2013) - La Jolla Pharmaceutical Company (OTCQB: LJPC) ("La Jolla" and "Company"), a leader in the development of therapeutics that target galectin-3, announced today that the United States Patent and Trademark Office (USPTO) has issued a notice of allowance for claims covering its lead product candidate, GCS-100, from patent application number 13/588,932. The claims, which expire in 2025 without accounting for any potential patent term extension, provide proprietary protection for solutions comprised of purified modified pectin, with a defined average molecular weight range.

"This patent compliments our other issued patents and strengthens our position as the leader in the development of effective, pectin-based therapeutics," said James Rolke, Senior Director of Research and Development at La Jolla and inventor of the technology.

George Tidmarsh, M.D. Ph.D., President and Chief Executive Officer of La Jolla stated, "The allowance of these claims represents another step in building our proprietary protection of GCS-100 and modified pectin compositions derived from any source. We are prosecuting additional patent claims that may provide further protection of our lead role targeting galectin-3 with pectin-derived products."

La Jolla Pharmaceutical Company is building a pipeline of drug candidates based on modified pectin, a polysaccharide chemically related to the natural pectin found in plant cell walls. Modified pectin has the ability to bind and sequester the protein galectin-3, over-expression of which has been implicated in a number of human diseases including chronic organ failure and cancer. The modified pectin compositions described in patent '932 may have the advantages of improved therapeutic potency, purity and composition uniformity. The claims allowed in this patent cover such pectin compositions regardless of the intended therapeutic use.

The Company's intellectual property portfolio also includes two issued patents covering methods for preparing biologically active modified pectin, 2 pending patents describing modified pectin compositions, and 1 pending patent covering the method of reducing the rate of cancer growth by treating with a galectin inhibitor.

About La Jolla Pharmaceutical Company

La Jolla Pharmaceutical Company is a biopharmaceutical company dedicated to the development of medical treatments that significantly improve outcomes in patients with life-threatening diseases. GCS-100, the Company's lead product candidate, is a first-in-class inhibitor of galectin-3, a novel molecular target implicated in chronic organ failure and cancer. For more information on the Company please visit http://www.ljpc.com.

Forward Looking Statement Safe Harbor

This document contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements relate to future events or our future results of operations. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, which may cause actual results to be materially different from these forward-looking statements. The Company cautions readers not to place undue reliance on any such forward-looking statements, which speak only as of the date they were made. Certain of these risks, uncertainties, and other factors are described in greater detail in the Company's filings from time to time with the U.S. Securities and Exchange Commission (SEC), all of which are available free of charge on the SEC's web site http://www.sec.gov. These risks include, but are not limited to, risks relating to the development of GCS-100, the success and timing of future preclinical and clinical studies of this compound, and potential indications for which GCS-100 may be developed. Subsequent written and oral forward-looking statements attributable to the Company or to persons acting on its behalf are expressly qualified in their entirety by the cautionary statements set forth in the Company's reports filed with the SEC. The Company expressly disclaims any intent to update any forward-looking statements.

Company Contact

George F. Tidmarsh, M.D., Ph.D.

President & Chief Executive Officer

La Jolla Pharmaceutical Company

Phone: (858) 207-4264

Email: GTidmarsh@ljpc.com

Or

Chester S. Zygmont, III

Director of Finance

La Jolla Pharmaceutical Company

Phone: (858) 207-4264

Email: czygmont@ljpc.com